TCDMD: TRILUMINATE Deep Dive Clarifies 'Meaningful' Quality of Life Gains with Tricuspid TEER
In patients with severe tricuspid regurgitation (TR), transcatheter edge-to-edge repair (TEER) using the TriClip system (Abbott) substantially improves patient symptoms, functional status, and quality of life (QoL) through 1-year, according to new in-depth data from the TRILUMINATE pivotal trial.
The findings, presented in a late-breaking clinical trials session at TCT 2023, follow data from the same trial presented earlier in the meeting showing 1-year safety and efficacy of the procedure in additional patients randomized to TEER or medical therapy alone as well as those with complex anatomies treated with TEER.
“The results really do support that tricuspid TEER probably does improve the health status of patients, and I think it's just a matter of trying to find who are the right patients—who are the ones who are symptomatic from their TR who are going to be most likely to benefit—and targeting to those,” said Suzanne Arnold, MD, a cardiologist at Saint Luke’s Mid America Heart Institute, who presented the findings.
Read the full TCDMD article: TRILUMINATE Deep Dive Clarifies 'Meaningful' Quality of Life Gains with Tricuspid TEER